These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15301984)

  • 21. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
    Moreland LW; Weinblatt ME; Keystone EC; Kremer JM; Martin RW; Schiff MH; Whitmore JB; White BW
    J Rheumatol; 2006 May; 33(5):854-61. PubMed ID: 16541481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of early rheumatoid arthritis.
    Suresh E
    J Assoc Physicians India; 2007 May; 55():355-62. PubMed ID: 17844697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
    Akkoc N; van der Linden S; Khan MA
    Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):539-57. PubMed ID: 16777581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and management of rheumatoid arthritis.
    Rindfleisch JA; Muller D
    Am Fam Physician; 2005 Sep; 72(6):1037-47. PubMed ID: 16190501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM; Fleischmann RM; Van der Heijde D; Tesser JR; Peloso PM; Chon Y; White B
    J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS; Park YW; Park JJ; Kang YM; Nam EJ; Kim SI; Lee JH; Yoo WH; Lee SI
    Scand J Rheumatol; 2009; 38(1):11-4. PubMed ID: 19191187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S; Zaman T; Handa R
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

  • 35. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
    Scherer HU; Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of conventional drugs and biologic agents for Rheumatoid Arthritis.
    Amoroso A; Gigante A; Gianni C; Amoroso D; Zennaro D; Galluzzo S; Caccavo D
    Eur Rev Med Pharmacol Sci; 2003; 7(5):139-45. PubMed ID: 15214589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic strategies for rheumatoid arthritis.
    Smolen JS; Steiner G
    Nat Rev Drug Discov; 2003 Jun; 2(6):473-88. PubMed ID: 12776222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Development of standards by the Norwegian Society of Rheumatology. Control of disease modifying drugs].
    Kvien TK; Haga HJ; Kvalvik AG
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2315-8. PubMed ID: 8804206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DC-ART: improvement and sustained improvement in function.
    Tugwell P; Baker P
    J Rheumatol Suppl; 1994 Sep; 41():23-4; discussion 24-6. PubMed ID: 7799380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rheumatology. Part 2: The role of medication.
    Byrne J
    Prof Nurse; 1999 Feb; 14(5):353-8. PubMed ID: 10205553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.